While Lupin is “truly excited with the potential” ahead, the uncertainty around upcoming product launches paints a different financial picture.

Lupin’s CEO spoke of US drug shortages having led to recognition of the need for structural and regulatory support for viable pricing of generic drugs. She was also optimistic on the relaunch of a Myrbetriq generic after Astellas obtained a temporary restraining order against Lupin and Zydus just a few days post an at-risk launch by the latter two companies

Dr Reddy’s has launched the second US rival to Oracea, shortly after Lupin introduced the first generic doxycycline 40mg capsules following a favorable district court ruling.

Lupin has pushed into the Canadian biosimilars market with the launch of its Rymti rival to Amgen’s Enbrel. The launch is taking place via Lupin’s local partner Sandoz.